Bortezomib in patients with relapsed-refractory multiple myeloma (MM). Clinical observations.

被引：1
|
作者：
Kyrtsonis, MC
Sachanas, S
Vassilakopoulos, TP
Kafassi, N
Tzenou, T
Papadogiannis, A
Kalpadakis, C
Antoniadis, AG
Dimopoulou, MN
Angelopoulou, MK
Siakantaris, MP
Dimitriadou, EM
Kokoris, SI
Plata, E
Tsaftaridis, P
Panayiotidis, P
Pangalis, GA
机构：
[1] Natl & Kapodistrian Univ Athens, Dept Internal Med 1, Athens, Greece
[2] Natl & Kapodistrian Univ Athens, Dept Haematol, Athens, Greece
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.5193.5193
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5193
引用
收藏
页码：382B / 382B
页数：1
相关论文
共 50 条
  • [1] Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM)
    Offidani, Massimo
    Corvatta, Laura
    Maracci, Laura
    Liberati, Anna Marina
    Ballanti, Stelvio
    Attolico, Immacolata
    Caraffa, Patrizia
    Alesiani, Francesco
    di Toritto, Tommaso Caravita
    Gentili, Silvia
    Tosi, Patrizia
    Brunori, Marino
    Derudas, Daniele
    Ledda, Antonio
    Gozzetti, Alessandro
    Cellini, Claudia
    Malerba, Lara
    Mele, Anna
    Andriani, Alessandro
    Galimberti, Sara
    Mondello, Patrizia
    Pulini, Stefano
    Coppetelli, Ugo
    Fraticelli, Paolo
    Olivieri, Attilio
    Leoni, Pietro
    BLOOD, 2013, 122 (21)
  • [2] Therapy of relapsed and relapsed-refractory Multiple Myeloma
    Driessen, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 8 - 8
  • [3] Bendamustine, Bortezomib and Dexamethasone (BVD) in Patients with Relapsed-Refractory Multiple Myeloma (MM): Updated Results of a Multicenter Phase II Study
    Offidani, Massimo
    Maracci, Laura
    Corvatta, Laura
    Marina, Liberati Anna
    Ballanti, Stelvio
    Attolico, Imma
    Caraffa, Patrizia
    Alesiani, Francesco
    di Toritto, Tommaso Caravita
    Gentili, Silvia
    Tosi, Patrizia
    Brunori, Marino
    Derudas, Daniele
    Ledda, Antonio
    Gozzetti, Alessandro
    Cellini, Claudia
    Malerba, Lara
    Mele, Anna
    Felici, Stefano
    Galimberti, Sara
    Mondello, Patrizia
    Pulini, Stefano
    Coppetelli, Ugo
    Fraticelli, Paolo
    Rizzi, Rita
    Leoni, Pietro
    BLOOD, 2014, 124 (21)
  • [4] Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
    Ahn, Jae-Sook
    Jung, Sung-Hoon
    Lee, Seung-Shin
    Ahn, Seo-Yeon
    Yang, Deok-Hwan
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [5] Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
    M Offidani
    L Corvatta
    L Maracci
    A M Liberati
    S Ballanti
    I Attolico
    P Caraffa
    F Alesiani
    T Caravita di Toritto
    S Gentili
    P Tosi
    M Brunori
    D Derudas
    A Ledda
    A Gozzetti
    C Cellini
    L Malerba
    A Mele
    A Andriani
    S Galimberti
    P Mondello
    S Pulini
    U Coppetelli
    P Fraticelli
    A Olivieri
    P Leoni
    Blood Cancer Journal, 2013, 3 : e162 - e162
  • [6] Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
    Offidani, M.
    Corvatta, L.
    Maracci, L.
    Liberati, A. M.
    Ballanti, S.
    Attolico, I.
    Caraffa, P.
    Alesiani, F.
    di Toritto, T. Caravita
    Gentili, S.
    Tosi, P.
    Brunori, M.
    Derudas, D.
    Ledda, A.
    Gozzetti, A.
    Cellini, C.
    Malerba, L.
    Mele, A.
    Andriani, A.
    Galimberti, S.
    Mondello, P.
    Pulini, S.
    Coppetelli, U.
    Fraticelli, P.
    Olivieri, A.
    Leoni, P.
    BLOOD CANCER JOURNAL, 2013, 3 : e162 - e162
  • [7] Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)
    Lacy, Martha Q.
    LaPlant, Betsy R.
    Laumann, Kristina M.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Ailawadhi, Sikander
    Chanan-Khan, Asher
    Stewart, A. Keith
    Reeder, Craig B.
    Rajkumar, S. Vincent
    Mikhael, Joseph R.
    BLOOD, 2014, 124 (21)
  • [8] Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma
    Sorgiovanni, Ilaria
    Del Giudice, Maria Livia
    Galimberti, Sara
    Buda, Gabriele
    PHARMACEUTICALS, 2025, 18 (02)
  • [9] Bortezomib in Relapsed/Refractory Multiple Myeloma
    Shen, Z.
    Wang, L.
    Yan, H.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S62 - S62
  • [10] Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma
    Richardson, PGG
    Barlogie, B
    Berenson, J
    Singhal, S
    Jagannath, S
    Irwin, D
    Rajkumar, SV
    Hideshima, T
    Xiao, H
    Esseltine, D
    Schenkein, D
    Anderson, KC
    BLOOD, 2005, 106 (09) : 2977 - 2981
12345